Plain-English translation of NCT03188796 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The VITDALIZE Study is testing whether (vitamin D3) given in high doses can help critically ill patients survive better. Previous research suggested that patients with severe vitamin D deficiency might benefit from this treatment, but we need a larger study to be sure. You would receive either the medication or a placebo (an inactive look-alike) while in the intensive care unit.
An earlier study found that critically ill patients with severe vitamin D deficiency had better survival rates when given this medication, but the result wasn't definitive enough to change standard care. This larger trial will test whether this medication truly helps save lives in this vulnerable population.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either high-dose vitamin D3 or an identical-looking placebo. Both groups receive a loading dose at the start, then daily drops for 90 days while you're in the hospital and recovering. The research team will track your health and survival outcomes for at least 28 days after enrollment, with follow-up assessments over the 90-day period.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Austria